Administrative Management fiT
Prof. Dr. Sven Stegemann
Sven Stegemann is CEO of fiT - Leibniz Joint Lab First in Translation
Publications
| Titel/Autoren | DOI-LINK | Magazine | Jahre | |
|---|---|---|---|---|
|
The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach
C. Gallus, F. Ayuk, P. Beckhove, D. Besser, M. Bornhäuser, H. Büning, T. Cantz, C. Conrad, S. Eichmüller, T. Gazlig, H. Graessner, A. Grüters-Kieslich, N. Huber, M. Hudecek, T. Kurz, B. Lamprecht, E. Luger, U. Protzer, A. Schambach, R. Schäfer, P. Serrano, S. Stegemann, I. Stöckert, C. von Kalle, J. Weber and C. Baum
|
https://doi.org/10.1177/10430342261464845 | Human Gene Therapy | 2026 | |
|
"Platform Technologies and Regulatory Sandboxes, A Blueprint for Accelerated Innovation in EU Pharmaceutical Legislation"
"Dr. Maren von Fritschen, HTW Berlin | Dr. Florian Schmidt, LL.M., DG SANTE European Commission | Dr. Falk Ehmann, European Medicines Agency | Prof. Dr. Karl Broich, Bundesinstitut für Arzneimittel und Medizinprodukte | Prof. Dr. Stefan Vieths, Paul Ehrlich Institut | Prof. Dr. Martin Hildebrandt, TUM School of Medicine, BZKF | Prof. Dr. Sven Stegemann, Leibniz JointLab First in Translation | Dr. Mihai Bilanin, GSK, on behalf of EFPIA, Vaccines Europe"
|
pharmind | 2025 | ||
|
Patient Engagement in Pharmaceutical Development: Where are we? – Report from a symposium
S. Stegemann, A. B. Almarsdόttir, C. Vermehren
|
https://doi.org/10.1016/j.ejpb.2023.02.005 | European Journal of Pharmaceutics and Biopharmaceutics | 2023 |